New study from Sylvester Cancer, collaborators shows anti-cancer compound goes beyond current BTK inhibitors Peer-Reviewed Publication UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE “THIS NEW COMPOUND NOT ONLY INHIBITS THE CELLULAR MOLECULE BTK, BUT GOES FURTHER BY TAKING AIM AT THE TARGET AND DESTROYING IT,” SAID Justin Taylor, M.D., SYLVESTER HEMATOLOGIST-RESEARCHER AND THE STUDY’S SENIOR...
by eLife A cell-by-cell tapestry of prostate cancer progression, which the authors created by applying a technique called UMAP to the entire dataset from their study. Credit: Germanos et al. (CC BY 4.0) Researchers have characterized prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease—from its beginning to the point...
BAYLOR COLLEGE OF MEDICINE A multi-institution team of researchers led by scientists at Baylor College of Medicine has discovered a genetic signature that can identify drivers of poor outcomes in advanced estrogen-receptor positive (ER+) breast cancer, which could one day lead to personalized treatment for patients. The 24-gene signature detects the presence of mutations and translocations in...
by Institute of Cancer Research Fig. 1: CSDE1 is a positive modulator of VSV replication. A Hep3B cells were transfected with no siRNA, Negative control siRNA, or with [s15373 + 15374 siRNA] (2 CSDE1-specific siRNA)46 and levels of CSDE1 assayed by western blotting 24 or 48 h later. (Representative of three separate experiments). B–D Forty-eight hours following transfection with siRNA...
